At the news
? BULLISHIMPACT 7/10 DEFA14A filed May 1, 2026 at 16:00 ET
Esperion Therapeutics entered into a definitive agreement to be acquired by ARCHIMED for $3.16 per share in cash, plus contingent milestone payments of up to $100 million tied to future net sales performance. The transaction is expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals.
- Acquisition price of $3.16 per share in cash
- Contingent milestone payments of up to $100 million in aggregate
- Expected closing in Q3 2026
- Agreement and Plan of Merger dated May 1, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access